Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1

Masakazu Toi,Frances Boyle,Young-Hyuck Im,Mattea Reinisch,David Molthrop,Zefei Jiang,Ran Wei,Francisco Sapunar,Brenda R Grimes,Sarah Cassidy Nabinger,Stephen R D Johnston

DOI: https://doi.org/10.1093/oncolo/oyac234

2023-01-18

Abstract:The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients with HR+, HER2- early breast cancer at high risk of recurrence (ClinicalTrials.gov: NCT03155997 [monarchE]).